TIDES Europe 2024 Post-Event Report eBook — Process Development & Manufacturing: Capabilities and Best Practices
The fields of oligonucleotide, peptide, and mRNA therapeutics are experiencing unprecedented growth, driven by their transformative potential in treating complex diseases and delivering personalized medicine. As these modalities transition from discovery to commercialization, efficient process development and manufacturing practices become critical to ensure product quality, scalability, and regulatory compliance.
This year, TIDES Europe featured over 100 speakers of the industry's top scientists who presented the latest science and industry updates across the entire spectrum from discovery, preclinical, and clinical development through CMC, manufacturing, and commercialization of therapeutics and vaccines for oligos, peptides, and mRNA and genome editing products.
Our 2024 content cross-pollinated expertise across the spectrum of Oligonucleotides, Peptides, mRNA, and Genome Editing. The TIDES Europe 2024 program featured concurrent tracks covering 6 scientific themes including in-depth development strategies, trends, and technologies across oligonucleotides, peptides, mRNA, and genome editing spaces.
This eBook highlights key moments of the event and looks at the significance of the research and insights shared in Hamburg this year. Read on to get a sense of what the buzz was like on-site and learn more about the industry-shaping discussions that were shared at TIDES Europe.
We hope to see you next year at TIDES Europe on November 11-13, 2025, at the Congress Center Basel in Basel, Switzerland.
Click to read the TIDES Europe 2024 Post-Event Report eBook — Process Development & Manufacturing: Capabilities and Best Practices
